BP
TCRT icon

Ballentine Partners’s Alaunos Therapeutics TCRT Stock Holding History

Ballentine Partners’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-181
Closed -$87K – 377
2018
Q3 		$87K Hold
181
– – ﹤0.01% 352
2018
Q2 		$82K Hold
181
– – ﹤0.01% 337
2018
Q1 		$106K Hold
181
– – 0.01% 345
2017
Q4 		$113K Hold
181
– – 0.01% 355
2017
Q3 		$167K Hold
181
– – 0.01% 364
2017
Q2 		$162K Buy
+181
New +$177K 0.01% 358
2013
Q3 		– Sell
-146
Closed -$46K – 140
2013
Q2 		$46K Buy
+146
New +$40.5K 0.01% 126

Other funds holding TCRT

MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MVP
Miller Value Partners Sarasota, Florida $383M AUM 38.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TS
Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Ballentine Partners's TCRT Position: Q4 2018 in Review

Ballentine Partners sold out of Alaunos Therapeutics (TCRT) in Q4 2018, closing a stake of 181 shares — an estimated $87K sold.

Ballentine Partners first reported a position in TCRT in Q2 2013 and held it in 7 quarters. The position peaked at $167K in Q3 2017. 137 funds tracked by Wall St. Rank hold TCRT as of Q4 2018.

  • Ballentine Partners reported no remaining Alaunos Therapeutics position as of Q4 2018 after selling out during the quarter.
  • Ballentine Partners sold 181 Alaunos Therapeutics shares in Q4 2018, an estimated $87K.
  • Ballentine Partners first reported a position in Alaunos Therapeutics in Q2 2013 and held it in 7 quarters.
  • Ballentine Partners's Alaunos Therapeutics position peaked at $167K in Q3 2017.
  • 137 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q4 2018.

Based on Ballentine Partners's 13F filing for Q4 2018, filed 4 Feb 2019.